Diarylquinoline
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2020 (NCT04493671)
Timeline
Indications
Mechanism of action
- ATP synthaseINHIBITOR
ATP synthase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cc(OC)nc(OC)c2OC)cc(OC)n1- Mol. weight
- 657.56 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4553146 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06058299 | Phase 2 | Oct 31, 2023 | Global Alliance for TB Drug Development, TB Alliance |
| NCT05526911 | Phase 1 | Jul 21, 2022 | Global Alliance for TB Drug Development |
| NCT04890535 | Phase 1 | Dec 1, 2020 | Global Alliance for TB Drug Development, QPS |
| NCT04493671 | Phase 1 | Jun 8, 2020 | Global Alliance for TB Drug Development |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Global Alliance for TB Drug Development | Academic/Hospital | 4 | 4 | 2 | 2020 |
| QPS | For profit | 1 | 0 | 1 | 2020 |
| TB Alliance | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1